M H Cullen
Overview
Explore the profile of M H Cullen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
890
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Naurois J, Novitzky-Basso I, Gill M, Marti F, Cullen M, Roila F
Ann Oncol
. 2010 Jun;
21 Suppl 5:v252-6.
PMID: 20555092
No abstract available.
2.
Owadally W, Sydes M, Radford J, Hancock B, Cullen M, Stenning S, et al.
Ann Oncol
. 2009 Aug;
21(3):568-573.
PMID: 19684105
Background: This analysis was undertaken to assess the relationship between the dose intensity (DI) of initial chemotherapy and outcome in a large cohort of patients with advanced Hodgkin lymphoma treated...
3.
Marti F, Cullen M, Roila F
Ann Oncol
. 2009 May;
20 Suppl 4:166-9.
PMID: 19454445
No abstract available.
4.
Hussain S, Palmer D, Swinson D, Riley P, Wills A, Brown C, et al.
Oncol Rep
. 2008 Jun;
20(1):233-7.
PMID: 18575742
In response to increasing pressure on inpatient services and a meta-analysis indicating that cisplatin (C) is superior to carboplatin, we report a phase II trial of gemcitabine (G) and split-dose...
5.
Cullen M, Zatloukal P, Sorenson S, Novello S, Fischer J, Joy A, et al.
Ann Oncol
. 2008 Feb;
19(5):939-45.
PMID: 18283036
Background: This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy....
6.
Mead G, Cullen M, Huddart R, Harper P, Rustin G, Cook P, et al.
Br J Cancer
. 2005 Jul;
93(2):178-84.
PMID: 15999102
This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic germ cell cancer (GCC) who have failed initial BEP (bleomycin,...
7.
Dearnaley D, Fossa S, Kaye S, Cullen M, Harland S, Sokal M, et al.
Br J Cancer
. 2005 Jun;
92(12):2107-13.
PMID: 15928672
Adjuvant BEP (bleomycin, etoposide, cisplatin) is effective treatment for high-risk clinical stage I (HRCS1) non-seminomatous germ cell tumours (NSGCT), but the known toxicities of etoposide, and the expansion of the...
8.
Bessell E, Burton A, Haynes A, Glaholm J, Child J, Cullen M, et al.
Ann Oncol
. 2003 Feb;
14(2):258-67.
PMID: 12562653
Background: The aim of this study was to determine in a randomised trial whether there is any significant difference in toxicity between modified CHOP and MCOP chemotherapy in elderly patients...
9.
Billingham L, Bathers S, Burton A, Bryan S, Cullen M
Lung Cancer
. 2002 Jul;
37(2):219-25.
PMID: 12140146
In a recently published randomised trial of chemotherapy versus palliative care in advanced non-small cell lung cancer (the MIC2 trial), chemotherapy was shown to prolong survival without compromising quality of...
10.
Billingham L, Cullen M
Ann Oncol
. 2002 Feb;
12(12):1671-5.
PMID: 11843243
Background: Cisplatin-based chemotherapy improves survival in advanced non-small-cell lung cancer. Using data from phase III trials of mitomycin, ifosfamide and cisplatin, this paper investigates whether the beneficial effect of chemotherapy...